Northwestern Mutual Wealth Management’s BioXcel Therapeutics BTAI Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28	Hold	21	–	–	﹤0.01%	4061
2025 Q4	$34	Hold	21	–	–	﹤0.01%	3926
2025 Q3	$54	Hold	21	–	–	﹤0.01%	3730
2025 Q2	$38	Hold	21	–	–	﹤0.01%	3590
2025 Q1	$43	Hold	21	–	–	﹤0.01%	3589
2024 Q4	$127	Hold	21	–	–	﹤0.01%	3474
2024 Q3	$207	Sell	21 -1	-5%	-$13	﹤0.01%	3440
2024 Q2	$452	Buy	22 +1	+5%	+$33	﹤0.01%	3298
2024 Q1	$959	Hold	21	–	–	﹤0.01%	3188
2023 Q4	$1K	Sell	21 -88	-81%	-$4.89K	﹤0.01%	3170
2023 Q3	$4.4K	Hold	109	–	–	﹤0.01%	2787
2023 Q2	$11.6K	Hold	109	–	–	﹤0.01%	2519
2023 Q1	$32.5K	Hold	109	–	–	﹤0.01%	2096
2022 Q4	$37.4K	Buy	109 +88	+419%	+$21.3K	﹤0.01%	2011
2022 Q3	$4K	Buy	+21	New	+$4.88K	﹤0.01%	2728
2021 Q3	–	Sell	-2	Closed	-$1K	–	3020
2021 Q2	$1K	Buy	+2	New	+$1.09K	﹤0.01%	2867

Other funds holding BTAI

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northwestern Mutual Wealth Management's BTAI Position: Q1 2026 in Review

Northwestern Mutual Wealth Management held its BioXcel Therapeutics (BTAI) position steady in Q1 2026 at 21 shares worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #4061.

Northwestern Mutual Wealth Management first reported a position in BTAI in Q2 2021 and has held it in 16 quarters since. The position peaked at $37.4K in Q4 2022. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

Northwestern Mutual Wealth Management held 21 shares of BioXcel Therapeutics worth $28 as of Q1 2026.
Northwestern Mutual Wealth Management left its BioXcel Therapeutics share count unchanged in Q1 2026.
BioXcel Therapeutics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #4061 holding.
Northwestern Mutual Wealth Management first reported a position in BioXcel Therapeutics in Q2 2021 and has held it in 16 quarters since.
Northwestern Mutual Wealth Management's BioXcel Therapeutics position peaked at $37.4K in Q4 2022.
40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.